0913693 B.C. Ltd. (REPCF)
OTCMKTS · Delayed Price · Currency is USD
0.000001
0.00 (0.00%)
At close: Oct 19, 2026
0913693 B.C. Revenue
0913693 B.C. had revenue of 88.43K CAD in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to 353.74K. In the year 2025, 0913693 B.C. had annual revenue of 353.74K. That makes 0913693 B.C. the 45,286th largest company in the world by revenue and 6,569th in the United States.
Revenue
353.74K CAD
Revenue Growth
n/a
P/S Ratio
0.00
Revenue / Employee
353.74K CAD
Employees
1
Market Cap
74.00 USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 353.74K | -1.00 | - |
| Dec 31, 2024 | 353.74K | 1.00 | - |
| Dec 31, 2023 | 353.74K | - | - |
| Dec 31, 2022 | 353.74K | - | - |
| Dec 31, 2021 | 353.74K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RVL Pharmaceuticals | 36.92M |
| Gelesis Holdings | 12.14M |
| Infinity Pharmaceuticals | 2.57M |
| Genocea Biosciences | 1.91M |
| Baudax Bio | 1.27M |
| Cardax | 500.71K |
| Iterum Therapeutics | 390.00K |
| Panacos Pharmaceuticals | 99.00K |
0913693 B.C. News
- 3 years ago - RepliCel Provides Corporate Update - Accesswire
- 4 years ago - DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections - Accesswire
- 4 years ago - CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing - Accesswire
- 4 years ago - Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing - Accesswire
- 4 years ago - RepliCel Announces Material Patent Milestones - Accesswire
- 4 years ago - RepliCel Closed Final Tranche of Strategic Investment Commitment - Accesswire
- 4 years ago - RepliCel Terminates License Agreement with Shiseido - Accesswire
- 4 years ago - RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing - Accesswire